Table V.
Pharmacological treatment administered after coronary artery bypass grafting (CABG)
| Group of drugs | Before propensity matching | After propensity matching | ||||
|---|---|---|---|---|---|---|
| IGM (707) | Non-IGM (504) | P-value | IGM (243) | Non-IGM (230) | P-value | |
| ASA | 629 (89.0%) | 480 (95.2%) | < 0.001 | 216 (88.9%) | 216 (93.9%) | 0.052 |
| β-blocker | 646 (91.4%) | 483 (95.8%) | 0.002 | 226 (93%) | 220 (95.7%) | 0.215 |
| ACE inhibitor | 566 (80.1%) | 433 (85.9%) | 0.008 | 194 (79.8%) | 204 (88.7%) | 0.008 |
| Sartan | 33 (2.8%) | 4 (1.0%) | 0.027 | 9 (3.7%) | 1 (0.4%) | 0.014 |
| Statin | 607 (85.9%) | 474 (94.0%) | < 0.001 | 210 (86.4%) | 217 (94.3%) | 0.004 |
| Ca-blocker | 129 (18.2%) | 67 (13.3%) | 0.021 | 48 (19.8%) | 36 (15.7%) | 0.243 |
| Diuretic | 575 (81.3%) | 413 (81.9%) | 0.786 | 198 (81.5%) | 198 (86.1%) | 0.175 |
| Aldosterone antagonist | 32 (4.5%) | 18 (3.6%) | 0.41 | 13 (5.3%) | 6 (2.6%) | 0.129 |
| LMWH | 213 (30.1%) | 166 (32.9%) | 0.299 | 76 (31.3%) | 68 (29.6%) | 0.686 |
| Metformin | 70 (9.9%) | 24 (9.9%) | ||||
| Insulin | 157 (22.3%) | 58 (24%) | ||||
ACE – angiotensin-converting enzyme, ASA – acetylsalicylic acid, Ca-blocker – calcium channel blocker, IGM – impaired glucose metabolism, LMWH – low molecular weight heparin.